

Special Issue

Recent Trends in Antibiotic Drug Development

Message from the Guest Editor

The increasing number of life-threatening infections due to resistant Gram-positive and Gram-negative pathogens is becoming more and more alarming. In the last 50 years, only a small number of new chemical classes of antibacterial agents have reached clinical practice, while at the same time, the number of multi-drug-resistant bacteria is rising. In 2017 the World Health Organisation published a list of bacteria for which new antibiotics are urgently needed. Among these, Gram-negative carbapenem-resistant *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacteriaceae* have the highest, critical level of priority, followed by the Gram-positive *Staphylococcus aureus* and *Enterococcus faecium* resistant strains. New antibacterial drugs with novel mechanisms of action and novel strategies are thus needed to successfully fight these pathogens in the future. The focus of this Special Issue in *Pharmaceutics* will be devoted to recent advances in the development of small molecules as well as alternative strategies for treating infections with Gram-positive and Gram-negative bacteria.

Guest Editor

Dr. Tihomir Tomašič

Faculty of Pharmacy, University of Ljubljana, Kongresni trg 12, 1000 Ljubljana, Slovenia

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/65166

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).